Utama › Neoplasma Mieloproliferatif › Texas › Houston
Kajian klinikal Neoplasma Mieloproliferatif di Houston, TX
16 kajian untuk Neoplasma Mieloproliferatif sedang mencari peserta di lokasi dalam dan sekitar Houston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Mengambil pesertaFasa 1
- The University of Texas, MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Mengambil pesertaKajian pemerhatian
- Texas Children's Hospital, Houston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Mengambil pesertaFasa 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Mengambil pesertaFasa 1/2
- MD Anderson, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Mengambil pesertaFasa 1
- M D Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Mengambil pesertaFasa 2
- The University of Texas MD Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Mengambil pesertaFasa 1/2
- M D Anderson Cancer Center, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Mengambil pesertaFasa 2
- M D Anderson Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
Mengambil pesertaKajian pemerhatian
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Mengambil pesertaFasa 1
- University of Texas M. D. Anderson Cancer Center, Houston
Asciminib Roll-over Study
Mengambil pesertaFasa 4
- Uni Of TX MD Anderson Cancer Cntr, Houston
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Mengambil pesertaFasa 2
- M D Anderson Cancer Center, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Mengambil pesertaFasa 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Mengambil pesertaFasa 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Mengambil pesertaFasa 1
- The University of Texas MD Anderson Cancer Center, Houston
Kajian Neoplasma Mieloproliferatif di bandar lain
- New York City, NY15 kajian
- Boston, MA14 kajian
- Milwaukee, WI10 kajian
- Miami, FL10 kajian
- Chicago, IL9 kajian
- Durham, NC9 kajian
- Baldwin Park, CA9 kajian
- Seattle, WA9 kajian
- Atlanta, GA8 kajian
- Tampa, FL8 kajian
- Birmingham, AL8 kajian
- Columbus, OH8 kajian
Kajian lain di Houston
- Kanser Paru-paru Bukan Sel Kecil145 kajian
- Kanser Payudara126 kajian
- Kanser (semua jenis)121 kajian
- Kanser Metastatik104 kajian
- Kanser Kolorektal102 kajian
- Kanser Ovari89 kajian
- Leukemia Mieloid Akut85 kajian
- Kanser Paru-paru78 kajian
- Kanser Prostat76 kajian
- Kanser Endometrium68 kajian
- Kanser Pankreas61 kajian
- Melanoma59 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.